Review
. 2022 Feb; 24(2):264-279.
doi: 10.1007/s11307-021-01688-9.

Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future

Zhongquan Cheng 1 Yang Du 2 Leyi Yu 1 Zhu Yuan 3 Jie Tian 4 
Affiliations
  • PMID: 35102468
  •     122 References
  •     1 citations

Abstract

With the application of mono-immunotherapy in cancer, particularly immune checkpoint inhibitors, improved outcomes have been achieved. However, there are several limitations to immunotherapy, such as a poor response to the drugs, immune resistance, and immune-related adverse events. In recent years, studies of preclinical animal models and clinical trials have demonstrated that immune checkpoint inhibitors for breast cancer can significantly prolong the overall survival and quality of patients' lives. Meanwhile, combined immune checkpoint inhibitor treatment has attracted researchers' attention and showed great potential in the comprehensive treatment of breast cancer patients. Additionally, noninvasive imaging enables physicians to predict response to combined immunotherapeutic drugs, achieve treatment efficacy, and lead to better clinical management. Herein, we review the background of combined immune checkpoint inhibitor therapy and summarize its targeted imaging as well as progress in noninvasive imaging aimed at evaluating therapeutic outcomes. Finally, we describe several factors that may influence the outcome of this combined immunotherapy, the future direction of medical imaging, and the potential application of artificial intelligence in breast cancer. With further development of noninvasive imaging for the guidance of combined immune checkpoint inhibitors, cures for this disease may be achieved.

Keywords: Breast cancer; Combined immunotherapy; Immune checkpoint inhibitor; Noninvasive imaging.

Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.
Xu Lei, Yu Lei, +6 authors, Hua-Bing Tan.
Cancer Lett, 2019 Nov 16; 470. PMID: 31730903
Review.
Understanding the tumor immune microenvironment (TIME) for effective therapy.
Mikhail Binnewies, Edward W Roberts, +15 authors, Matthew F Krummel.
Nat Med, 2018 Apr 25; 24(5). PMID: 29686425    Free PMC article.
Highly Cited. Review.
Cancer immunotherapy using checkpoint blockade.
Antoni Ribas, Jedd D Wolchok.
Science, 2018 Mar 24; 359(6382). PMID: 29567705    Free PMC article.
Highly Cited. Review.
Immunotherapy in melanoma: Recent advances and future directions.
C Franklin, E Livingstone, +2 authors, D Schadendorf.
Eur J Surg Oncol, 2016 Oct 23; 43(3). PMID: 27769635
Highly Cited. Review.
Immunotherapy in Hodgkin Lymphoma: The Road Ahead.
Stephen M Ansell.
Trends Immunol, 2019 Apr 06; 40(5). PMID: 30948348
Review.
Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.
Vinay Prasad, Victoria Kaestner.
Semin Oncol, 2017 Sep 20; 44(2). PMID: 28923211
Review.
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
Charles L Vogel, Melody A Cobleigh, +10 authors, Michael Press.
J Clin Oncol, 2002 Feb 01; 20(3). PMID: 11821453
Highly Cited.
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.
Francis W Hunter, Hilary R Barker, +5 authors, Stephen M F Jamieson.
Br J Cancer, 2019 Dec 17; 122(5). PMID: 31839676    Free PMC article.
Review.
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.
Javier Cortés, Pierre Fumoleau, +15 authors, José Baselga.
J Clin Oncol, 2012 Mar 07; 30(14). PMID: 22393084
Highly Cited.
Imaging of Cancer Immunotherapy: Current Approaches and Future Directions.
Mizuki Nishino, Hiroto Hatabu, F Stephen Hodi.
Radiology, 2018 Nov 21; 290(1). PMID: 30457485    Free PMC article.
Review.
Biomarkers in preclinical cancer imaging.
Monique R Bernsen, Klazina Kooiman, +2 authors, Marion de Jong.
Eur J Nucl Med Mol Imaging, 2015 Feb 13; 42(4). PMID: 25673052    Free PMC article.
Review.
Nanoparticles for imaging and treatment of metastatic breast cancer.
Qingxin Mu, Hui Wang, Miqin Zhang.
Expert Opin Drug Deliv, 2016 Jul 13; 14(1). PMID: 27401941    Free PMC article.
Review.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
Regulation and Function of the PD-L1 Checkpoint.
Chong Sun, Riccardo Mezzadra, Ton N Schumacher.
Immunity, 2018 Mar 22; 48(3). PMID: 29562194    Free PMC article.
Highly Cited. Review.
Elements of cancer immunity and the cancer-immune set point.
Daniel S Chen, Ira Mellman.
Nature, 2017 Jan 20; 541(7637). PMID: 28102259
Highly Cited. Review.
Immunotherapy and targeted therapy combinations in metastatic breast cancer.
Francisco J Esteva, Vanessa M Hubbard-Lucey, Jun Tang, Lajos Pusztai.
Lancet Oncol, 2019 Mar 08; 20(3). PMID: 30842061
Highly Cited. Review.
Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
Feifei Teng, Xiangjiao Meng, Li Kong, Jinming Yu.
Cancer Lett, 2017 Nov 21; 414. PMID: 29155348
Systematic Review.
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade.
Mohammad Rashidian, Martin W LaFleur, +13 authors, Hidde L Ploegh.
Proc Natl Acad Sci U S A, 2019 Aug 04; 116(34). PMID: 31375632    Free PMC article.
CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models.
Lotte K Kristensen, Camilla Fröhlich, +8 authors, Andreas Kjaer.
Theranostics, 2019 Nov 23; 9(26). PMID: 31754392    Free PMC article.
Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model.
Yang Du, Ting Sun, +5 authors, Jie Tian.
Int J Nanomedicine, 2017 Dec 05; 12. PMID: 29200846    Free PMC article.
Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.
Christopher G England, Emily B Ehlerding, +7 authors, Weibo Cai.
J Nucl Med, 2016 Aug 06; 58(1). PMID: 27493273    Free PMC article.
Highly Cited.
Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-64Cu/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy.
Yang Du, Xiaolong Liang, +4 authors, Jie Tian.
Mol Pharm, 2017 Oct 11; 14(11). PMID: 29016143
Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
Wenfa Huang, Ran Ran, Bin Shao, Huiping Li.
Breast Cancer Res Treat, 2019 Jul 31; 178(1). PMID: 31359214
Review.
Trophoblast CD274 (B7-H1) is differentially expressed across gestation: influence of oxygen concentration.
Lesya M Holets, Joan S Hunt, Margaret G Petroff.
Biol Reprod, 2005 Oct 28; 74(2). PMID: 16251499
The role of exosomal PD-L1 in tumor progression and immunotherapy.
Feiting Xie, Mengxue Xu, +2 authors, Shengjun Wang.
Mol Cancer, 2019 Oct 28; 18(1). PMID: 31647023    Free PMC article.
Highly Cited. Review.
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.
A N Niemeijer, D Leung, +20 authors, A J de Langen.
Nat Commun, 2018 Nov 09; 9(1). PMID: 30405135    Free PMC article.
Highly Cited.
Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments.
Yang Du, Xiaolong Liang, +4 authors, Jie Tian.
Cancer Lett, 2017 Nov 28; 414. PMID: 29175457
Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect.
Yang Du, Yinhua Jin, +3 authors, Jie Tian.
Eur Radiol, 2018 Dec 07; 29(8). PMID: 30506221    Free PMC article.
Review.
Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer.
Anders Josefsson, Jessie R Nedrow, +5 authors, George Sgouros.
Cancer Res, 2015 Nov 12; 76(2). PMID: 26554829    Free PMC article.
Highly Cited.
PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
Wojciech G Lesniak, Samit Chatterjee, +4 authors, Sridhar Nimmagadda.
Bioconjug Chem, 2016 Jul 28; 27(9). PMID: 27458027    Free PMC article.
Peptide-Based 68Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer.
Ravindra A De Silva, Dhiraj Kumar, +7 authors, Sridhar Nimmagadda.
Mol Pharm, 2018 Jul 25; 15(9). PMID: 30037229    Free PMC article.
Development of [18F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide.
Wojciech G Lesniak, Ronnie C Mease, +7 authors, Sridhar Nimmagadda.
Mol Imaging, 2019 Jun 13; 18. PMID: 31187691    Free PMC article.
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.
Frederike Bensch, Elly L van der Veen, +18 authors, Elisabeth G E de Vries.
Nat Med, 2018 Nov 28; 24(12). PMID: 30478423
Highly Cited.
CTLA-4: a moving target in immunotherapy.
Behzad Rowshanravan, Neil Halliday, David M Sansom.
Blood, 2017 Nov 10; 131(1). PMID: 29118008    Free PMC article.
Highly Cited. Review.
What did we learn from CTLA-4 insufficiency on the human immune system?
Noriko Mitsuiki, Charlotte Schwab, Bodo Grimbacher.
Immunol Rev, 2018 Dec 20; 287(1). PMID: 30565239
Review.
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
Udupi A Ramagopal, Weifeng Liu, +10 authors, Steven C Almo.
Proc Natl Acad Sci U S A, 2017 May 10; 114(21). PMID: 28484017    Free PMC article.
ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer.
Emily B Ehlerding, Christopher G England, +6 authors, Weibo Cai.
Mol Pharm, 2017 Apr 08; 14(5). PMID: 28388076    Free PMC article.
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells.
Mohammad Rashidian, Jessica R Ingram, +11 authors, Hidde L Ploegh.
J Exp Med, 2017 Jul 02; 214(8). PMID: 28666979    Free PMC article.
Highly Cited.
Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis.
Ting Sun, Wenjia Zhang, +4 authors, Huadan Xue.
Mol Cancer Ther, 2019 Dec 05; 19(3). PMID: 31796506
Tim-3, Lag-3, and TIGIT.
Nicole Joller, Vijay K Kuchroo.
Curr Top Microbiol Immunol, 2017 Sep 14; 410. PMID: 28900677    Free PMC article.
Review.
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Shuang Qin, Linping Xu, +3 authors, Suxia Luo.
Mol Cancer, 2019 Nov 07; 18(1). PMID: 31690319    Free PMC article.
Highly Cited. Review.
B7-H3 in Cancer - Beyond Immune Regulation.
Karine Flem-Karlsen, Øystein Fodstad, Ming Tan, Caroline E Nunes-Xavier.
Trends Cancer, 2018 Jun 05; 4(6). PMID: 29860983
Review.
Immune checkpoint blockade opens a new way to cancer immunotherapy.
Sanam Sadreddini, Behzad Baradaran, +4 authors, Leili Aghebati-Maleki.
J Cell Physiol, 2018 Dec 05; 234(6). PMID: 30511409
Review.
Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a.
Ingrid Julienne Georgette Burvenich, Sagun Parakh, +13 authors, Andrew Mark Scott.
Theranostics, 2018 Aug 22; 8(15). PMID: 30128047    Free PMC article.
Efficacy of Affibody-Based Ultrasound Molecular Imaging of Vascular B7-H3 for Breast Cancer Detection.
Rakesh Bam, Patrick S Lown, +8 authors, Lotfi Abou-Elkacem.
Clin Cancer Res, 2020 Jan 12; 26(9). PMID: 31924738    Free PMC article.
Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab.
Antoni Ribas, Matthias R Benz, +7 authors, Johannes Czernin.
J Nucl Med, 2010 Feb 13; 51(3). PMID: 20150263
Molecular Imaging of Biomarkers in Breast Cancer.
Gary A Ulaner, Chris C Riedl, +3 authors, Wolfgang Weber.
J Nucl Med, 2016 Feb 03; 57 Suppl 1. PMID: 26834103    Free PMC article.
Review.
Prospects for combining targeted and conventional cancer therapy with immunotherapy.
Philip Gotwals, Scott Cameron, +9 authors, Glenn Dranoff.
Nat Rev Cancer, 2017 Mar 25; 17(5). PMID: 28338065
Highly Cited. Review.
Tumour-intrinsic resistance to immune checkpoint blockade.
Anusha Kalbasi, Antoni Ribas.
Nat Rev Immunol, 2019 Oct 02; 20(1). PMID: 31570880    Free PMC article.
Highly Cited. Review.
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll.
Cancer Cell, 2015 Apr 11; 27(4). PMID: 25858804    Free PMC article.
Highly Cited. Review.
Breast Cancer Treatment: A Review.
Adrienne G Waks, Eric P Winer.
JAMA, 2019 Jan 23; 321(3). PMID: 30667505
Highly Cited. Review.
Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity.
Orneala Bakos, Christine Lawson, Samuel Rouleau, Lee-Hwa Tai.
J Immunother Cancer, 2018 Sep 05; 6(1). PMID: 30176921    Free PMC article.
Review.
Awareness and current knowledge of breast cancer.
Muhammad Akram, Mehwish Iqbal, Muhammad Daniyal, Asmat Ullah Khan.
Biol Res, 2017 Oct 04; 50(1). PMID: 28969709    Free PMC article.
Highly Cited. Review.
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.
Sherene Loi, Sandra Pommey, +4 authors, John Stagg.
Proc Natl Acad Sci U S A, 2013 Jun 19; 110(27). PMID: 23776241    Free PMC article.
Highly Cited.
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.
Jing Liu, Stephen J Blake, +8 authors, Michele W L Teng.
Cancer Discov, 2016 Sep 25; 6(12). PMID: 27663893
Highly Cited.
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.
Junjie Wu, David J Waxman.
Cancer Lett, 2018 Feb 08; 419. PMID: 29414305    Free PMC article.
Review.
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.
L Bracci, G Schiavoni, A Sistigu, F Belardelli.
Cell Death Differ, 2013 Jun 22; 21(1). PMID: 23787994    Free PMC article.
Highly Cited. Review.
Update on the role of ipilimumab in melanoma and first data on new combination therapies.
Michele Maio, Anna M Di Giacomo, Caroline Robert, Alexander M M Eggermont.
Curr Opin Oncol, 2013 Jan 10; 25(2). PMID: 23299197
Review.
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
Connie Kang, Yahiya Y Syed.
Drugs, 2020 Apr 06; 80(6). PMID: 32248356
Review.
Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment.
Gary J R Cook, Gurdip K Azad, Vicky Goh.
J Nucl Med, 2016 Feb 03; 57 Suppl 1. PMID: 26834098
Review.
Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix.
Noor Jailkhani, Jessica R Ingram, +6 authors, Richard O Hynes.
Proc Natl Acad Sci U S A, 2019 May 10; 116(28). PMID: 31068469    Free PMC article.
Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging.
Bruce J Tromberg, Zheng Zhang, +20 authors, ACRIN 6691 investigators.
Cancer Res, 2016 Aug 17; 76(20). PMID: 27527559    Free PMC article.
Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Zishuo I Hu, Alice Y Ho, Heather L McArthur.
Int J Radiat Oncol Biol Phys, 2017 Aug 18; 99(1). PMID: 28816141
Review.
Integration of radiation and immunotherapy in breast cancer - Treatment implications.
Jason C Ye, Silvia C Formenti.
Breast, 2017 Dec 19; 38. PMID: 29253718
Review.
The Reciprocity between Radiotherapy and Cancer Immunotherapy.
Yifan Wang, Zhi-Gang Liu, +6 authors, Wen Jiang.
Clin Cancer Res, 2018 Nov 11; 25(6). PMID: 30413527    Free PMC article.
Review.
Radiation and immunotherapy: a synergistic combination.
Anusha Kalbasi, Carl H June, Naomi Haas, Neha Vapiwala.
J Clin Invest, 2013 Jul 19; 123(7). PMID: 23863633    Free PMC article.
Highly Cited.
A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.
Alice Y Ho, Christopher A Barker, +11 authors, Heather L McArthur.
Cancer, 2019 Nov 21; 126(4). PMID: 31747077
Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
Priya Bhusari, Rakhee Vatsa, +5 authors, Jaya Shukla.
Int J Cancer, 2016 Nov 05; 140(4). PMID: 27813061
Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer.
A Weller, M E R O'Brien, +7 authors, N M deSouza.
Eur J Cancer, 2016 Mar 27; 59. PMID: 27016624
Review.
Enhancing CAR T-cell therapy through cellular imaging and radiotherapy.
Il Minn, Steven P Rowe, Martin G Pomper.
Lancet Oncol, 2019 Aug 01; 20(8). PMID: 31364596
Review.
Assessing the interactions between radiotherapy and antitumour immunity.
Clemens Grassberger, Susannah G Ellsworth, +2 authors, Jay S Loeffler.
Nat Rev Clin Oncol, 2019 Jun 28; 16(12). PMID: 31243334
Review.
Combining cancer immunotherapy and targeted therapy.
Antoni Ribas, Jedd D Wolchok.
Curr Opin Immunol, 2013 Apr 09; 25(2). PMID: 23561594    Free PMC article.
Review.
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
Deborah A Knight, Shin Foong Ngiow, +11 authors, Mark J Smyth.
J Clin Invest, 2013 Mar 05; 123(3). PMID: 23454771    Free PMC article.
Highly Cited.
Targeted adjuvant therapy in breast cancer.
Dimitrios Zardavas, Konstantinos Tryfonidis, Theodora Goulioti, Martine Piccart.
Expert Rev Anticancer Ther, 2016 Oct 16; 16(12). PMID: 27741402
Review.
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
George W Sledge, Masakazu Toi, +15 authors, Antonio Llombart-Cussac.
J Clin Oncol, 2017 Jun 06; 35(25). PMID: 28580882
Highly Cited.
CDK4/6 inhibition triggers anti-tumour immunity.
Shom Goel, Molly J DeCristo, +17 authors, Jean J Zhao.
Nature, 2017 Aug 17; 548(7668). PMID: 28813415    Free PMC article.
Highly Cited.
TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
Roisin M Connolly, Jeffrey P Leal, +20 authors, Vered Stearns.
J Clin Oncol, 2019 Feb 06; 37(9). PMID: 30721110    Free PMC article.
Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer.
Nadia Harbeck.
Breast, 2019 Dec 17; 48 Suppl 1. PMID: 31839172
Preclinical Imaging in Targeted Cancer Therapies.
Francesca Iommelli, Viviana De Rosa, +2 authors, Silvana Del Vecchio.
Semin Nucl Med, 2019 Sep 01; 49(5). PMID: 31470932
Review.
Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
Jaeyeon Choi, Wissam Beaino, +5 authors, Carolyn J Anderson.
J Nucl Med, 2018 Jul 01; 59(12). PMID: 29959213    Free PMC article.
Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Hongyan Jia, Cristina I Truica, +5 authors, Jin-Ming Yang.
Drug Resist Updat, 2017 Nov 18; 32. PMID: 29145974
Review.
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Marina Martinez, Edmund Kyung Moon.
Front Immunol, 2019 Feb 26; 10. PMID: 30804938    Free PMC article.
Highly Cited. Review.
Top 10 Challenges in Cancer Immunotherapy.
Priti S Hegde, Daniel S Chen.
Immunity, 2020 Jan 16; 52(1). PMID: 31940268
Review.
MMP-11 as a biomarker for metastatic breast cancer by immunohistochemical-assisted imaging mass spectrometry.
Raquel González de Vega, David Clases, +5 authors, Alfredo Sanz-Medel.
Anal Bioanal Chem, 2018 Sep 16; 411(3). PMID: 30218127
Diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer.
Joao V Horvat, Blanca Bernard-Davila, +11 authors, Katja Pinker.
J Magn Reson Imaging, 2019 Feb 28; 50(3). PMID: 30811717    Free PMC article.
64Cu2+ Ions as PET Probe: An Emerging Paradigm in Molecular Imaging of Cancer.
Rubel Chakravarty, Sudipta Chakraborty, Ashutosh Dash.
Mol Pharm, 2016 Oct 07; 13(11). PMID: 27709959
Review.
Cancer Immunoimaging with Smart Nanoparticles.
Yu-Chuan Ou, Xiaona Wen, Rizia Bardhan.
Trends Biotechnol, 2019 Dec 10; 38(4). PMID: 31812371
Review.
Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications.
Seyed Mohammadali Dadfar, Karolin Roemhild, +4 authors, Twan Lammers.
Adv Drug Deliv Rev, 2019 Jan 15; 138. PMID: 30639256    Free PMC article.
Highly Cited. Review.
Digital Mammography in Breast Cancer: Additive Value of Radiomics of Breast Parenchyma.
Hui Li, Kayla R Mendel, +2 authors, Maryellen L Giger.
Radiology, 2019 Feb 13; 291(1). PMID: 30747591    Free PMC article.
Precision Medicine and Radiogenomics in Breast Cancer: New Approaches toward Diagnosis and Treatment.
Katja Pinker, Joanne Chin, +2 authors, Linda Moy.
Radiology, 2018 May 22; 287(3). PMID: 29782246
Highly Cited. Review.
Combination cancer immunotherapies tailored to the tumour microenvironment.
Mark J Smyth, Shin Foong Ngiow, Antoni Ribas, Michele W L Teng.
Nat Rev Clin Oncol, 2015 Nov 26; 13(3). PMID: 26598942
Highly Cited. Review.
Editorial to the Special Issue Entitled "Imaging in Immunooncology".
Gilbert O Fruhwirth, Bettina Weigelin, Heike E Daldrup-Link, Vladimir Ponomarev.
Mol Imaging Biol, 2022 Mar 19; 24(2). PMID: 35303206    Free PMC article.